Glitazones represent an exception among antidiabetic drugs in that they target excess substrate metabolism and insulin sensitivity as pathogenic causes in the metabolic syndrome and type 2 diabetes as opposed to treating disease symptoms. This evidence concerns the gene INS and metabolic syndrome.